125 related articles for article (PubMed ID: 10830713)
1. Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: persistent transgene expression despite antibody generation.
Mukherjee S; Haenel T; Himbeck R; Scott B; Ramshaw I; Lake RA; Harnett G; Phillips P; Morey S; Smith D; Davidson JA; Musk AW; Robinson B
Cancer Gene Ther; 2000 May; 7(5):663-70. PubMed ID: 10830713
[TBL] [Abstract][Full Text] [Related]
2. Cytokine-armed vaccinia virus infects the mesothelioma tumor microenvironment to overcome immune tolerance and mediate tumor resolution.
Jackaman C; Nelson DJ
Cancer Gene Ther; 2010 Jun; 17(6):429-40. PubMed ID: 20150930
[TBL] [Abstract][Full Text] [Related]
3. Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant.
Puhlmann M; Brown CK; Gnant M; Huang J; Libutti SK; Alexander HR; Bartlett DL
Cancer Gene Ther; 2000 Jan; 7(1):66-73. PubMed ID: 10678358
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of combined vaccinia virus-mediated antitumor gene therapy with p53, IL-2, and IL-12 in a glioma model.
Chen B; Timiryasova TM; Andres ML; Kajioka EH; Dutta-Roy R; Gridley DS; Fodor I
Cancer Gene Ther; 2000 Nov; 7(11):1437-47. PubMed ID: 11129286
[TBL] [Abstract][Full Text] [Related]
5. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo.
Jacobs A; Tjuvajev JG; Dubrovin M; Akhurst T; Balatoni J; Beattie B; Joshi R; Finn R; Larson SM; Herrlinger U; Pechan PA; Chiocca EA; Breakefield XO; Blasberg RG
Cancer Res; 2001 Apr; 61(7):2983-95. PubMed ID: 11306477
[TBL] [Abstract][Full Text] [Related]
6. Dendritic cells infected with a vaccinia virus interleukin-2 vector secrete high levels of IL-2 and can become efficient antigen presenting cells that secrete high levels of the immunostimulatory cytokine IL-12.
Mukherjee S; Upham JW; Ramshaw I; Bundell C; van Bruggen I; Robinson BW; Nelson DJ
Cancer Gene Ther; 2003 Aug; 10(8):591-602. PubMed ID: 12872141
[TBL] [Abstract][Full Text] [Related]
7. Replication-deficient vaccinia virus gene therpay vector: evaluation of exogenous gene expression mediated by PUV-inactivated virus in glioma cells.
Timiryasova TM; Chen B; Fodor I
J Gene Med; 2001; 3(5):468-77. PubMed ID: 11601760
[TBL] [Abstract][Full Text] [Related]
8. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
O'Malley BW; Li D; McQuone SJ; Ralston R
Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
[TBL] [Abstract][Full Text] [Related]
9. Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: results of a phase 1 clinical trial.
Stewart AK; Lassam NJ; Quirt IC; Bailey DJ; Rotstein LE; Krajden M; Dessureault S; Gallinger S; Cappe D; Wan Y; Addison CL; Moen RC; Gauldie J; Graham FL
Gene Ther; 1999 Mar; 6(3):350-63. PubMed ID: 10435085
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity.
Slos P; De Meyer M; Leroy P; Rousseau C; Acres B
Cancer Gene Ther; 2001 May; 8(5):321-32. PubMed ID: 11477452
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of S100A11 gene expression impairs keratinocyte response against vaccinia virus through downregulation of the IL-10 receptor 2 chain.
Bin L; Howell MD; Kim BE; Hall CF; Streib JE; Leung DY
J Allergy Clin Immunol; 2009 Aug; 124(2):270-7, 277.e1. PubMed ID: 19577285
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of the intratumoral administration of recombinant canarypox viruses expressing B7.1 and interleukin 12 in patients with metastatic melanoma.
Triozzi PL; Allen KO; Carlisle RR; Craig M; LoBuglio AF; Conry RM
Clin Cancer Res; 2005 Jun; 11(11):4168-75. PubMed ID: 15930353
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of cytokine toxicity induced by vaccinia virus-mediated IL-2 and IL-12 antitumour immunotherapy.
Chen B; Timiryasova TM; Gridley DS; Andres ML; Dutta-Roy R; Fodor I
Cytokine; 2001 Sep; 15(6):305-14. PubMed ID: 11594797
[TBL] [Abstract][Full Text] [Related]
14. Recombinant adenovirus shedding after intratumoral gene transfer in lung cancer patients.
Griscelli F; Opolon P; Saulnier P; Mami-Chouaib F; Gautier E; Echchakir H; Angevin E; Le Chevalier T; Bataille V; Squiban P; Tursz T; Escudier B
Gene Ther; 2003 Mar; 10(5):386-95. PubMed ID: 12601393
[TBL] [Abstract][Full Text] [Related]
15. In vivo murine tumor gene delivery and expression by systemic recombinant vaccinia virus encoding interleukin-1beta.
Peplinski GR; Tsung AK; Casey MJ; Meko JB; Fredrickson TN; Buller RM; Norton JA
Cancer J Sci Am; 1996; 2(1):21-7. PubMed ID: 9166494
[TBL] [Abstract][Full Text] [Related]
16. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes.
McCart JA; Ward JM; Lee J; Hu Y; Alexander HR; Libutti SK; Moss B; Bartlett DL
Cancer Res; 2001 Dec; 61(24):8751-7. PubMed ID: 11751395
[TBL] [Abstract][Full Text] [Related]
17. Targeted delivery of a suicide gene to human colorectal tumors by a conditionally replicating vaccinia virus.
Foloppe J; Kintz J; Futin N; Findeli A; Cordier P; Schlesinger Y; Hoffmann C; Tosch C; Balloul JM; Erbs P
Gene Ther; 2008 Oct; 15(20):1361-71. PubMed ID: 18480846
[TBL] [Abstract][Full Text] [Related]
18. Clinical phase I intratumoral administration of two recombinant ALVAC canarypox viruses expressing human granulocyte-macrophage colony-stimulating factor or interleukin-2: the transgene determines the composition of the inflammatory infiltrate.
Hofbauer GF; Baur T; Bonnet MC; Tartour E; Burg G; Berinstein NL; Dummer R
Melanoma Res; 2008 Apr; 18(2):104-11. PubMed ID: 18337646
[TBL] [Abstract][Full Text] [Related]
19. Gene therapy eradicating distant disseminated micro-metastases by optimal cytokine expression in the primary lesion only: novel concepts for successful cytokine gene therapy.
Nagano S; Yuge K; Fukunaga M; Terazaki Y; Fujiwara H; Komiya S; Kosai K
Int J Oncol; 2004 Mar; 24(3):549-58. PubMed ID: 14767539
[TBL] [Abstract][Full Text] [Related]
20. A pilot study of systemic corticosteroid administration in conjunction with intrapleural adenoviral vector administration in patients with malignant pleural mesothelioma.
Sterman DH; Molnar-Kimber K; Iyengar T; Chang M; Lanuti M; Amin KM; Pierce BK; Kang E; Treat J; Recio A; Litzky L; Wilson JM; Kaiser LR; Albelda SM
Cancer Gene Ther; 2000 Dec; 7(12):1511-8. PubMed ID: 11228529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
